EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Selinexor With Anti-PD-1 Antibody as a Potentially Effective Regimen for Patients With Natural Killer/T-Cell Lymphoma Failing Prior L-Asparaginase and PD-1 Blockade

Rong Tao iD, Chuanxu Liu, Wenhao Zhang, Yang Zhu, Yujie Ma, Siguo Hao

The Oncologist · 2024

DOI: 10.1093/oncolo/oyad241 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Oncologist, 2024. Verfasst von Rong Tao und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, People's Republic of China. Hauptthemen laut MEDLINE: Lymphoma, Lymphoma, T-Cell. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Shanghai Municipal Education Commission.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Natural killer/T-cell lymphoma (NKTCL) is a rare and heterogeneous tumor type of non-Hodgkin’s lymphoma (NHL) with a poor clinical outcome. There is no standardized salvage treatment failing l-asparaginase-based regimens. Here we report our retrospective results of the combined use of selinexor and PD-1 blockade (tislelizumab) in 5 patients with NKTCL who had exhausted almost all available treatments. Patients and methods A total of 5 patients with relapsed/refractory(R/R) NK/T-cell lymphomas failing prior l-asparaginase and anti-PD-1 antibody were retrospectively collected. They were treated with at least one cycle of XPO1 inhibitor plus the same anti-PD-1 antibody. Anti-PD-1 antibody (Tislelizumab) was administrated at 200 mg on day 1 every 3 weeks and selinexor doses and schedules ranged from 40 mg weekly for 2 weeks per 21-day cycle to 60 mg weekly per cycle.

Results

Five patients with relapsed NKTCL with extensive organ involvement including 4 central nervous system (CNS) infiltration patients were included. Four patients achieved objective responses including 3 complete responses (CR) and 1 partial response (PR). After a median follow-up time of 14.5 (range, 5-22) months, 1 patient was still in remission with CR, and the other 4 patients discontinued due to disease progression with a median progression-free survival (PFS) of 6 months and median overall survival (OS) of 12 months. Four patients with CNS involvement achieved a median OS of 8 months. Our data suggest that selinexor in combination with an anti-PD-1 antibody is a promising small molecule and immunotherapy combination regimen for patients with relapsed or refractory NKTCL.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

LymphomaLymphoma, T-CellHumansAsparaginaseRetrospective StudiesProgrammed Cell Death 1 ReceptorNeoplasm Recurrence, LocalKiller Cells, NaturalAntineoplastic Combined Chemotherapy ProtocolsHydrazinesTriazoles

Stichwörter der Autor:innen

PD-1 blockadecentral nervous system involvementnatural killer/T-cell lymphomaselinexor

Substanzen

AsparaginaseProgrammed Cell Death 1 ReceptorselinexorHydrazinesTriazoles

Autor:innen und Institutionen

  • Department of Hematology, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, People's Republic of China.
  • Department of Lymphoma, Fudan University Shanghai Cancer Center, Shanghai, People's Republic of China.

ORCID-Profile: Rong Tao

Förderung

  • Shanghai Municipal Education Commission

Zitieren

APA

Tao, R., Liu, C., Zhang, W., Zhu, Y., Ma, Y., & Hao, S. (2024). Selinexor With Anti-PD-1 Antibody as a Potentially Effective Regimen for Patients With Natural Killer/T-Cell Lymphoma Failing Prior L-Asparaginase and PD-1 Blockade. The Oncologist. https://doi.org/10.1093/oncolo/oyad241

Vancouver

Tao R, Liu C, Zhang W, Zhu Y, Ma Y, Hao S. Selinexor With Anti-PD-1 Antibody as a Potentially Effective Regimen for Patients With Natural Killer/T-Cell Lymphoma Failing Prior L-Asparaginase and PD-1 Blockade. The Oncologist. 2024. doi:10.1093/oncolo/oyad241

BibTeX
@article{Tao2024,
  author = {Tao, Rong and Liu, Chuanxu and Zhang, Wenhao and Zhu, Yang and Ma, Yujie and Hao, Siguo},
  title = {Selinexor With Anti-PD-1 Antibody as a Potentially Effective Regimen for Patients With Natural Killer/T-Cell Lymphoma Failing Prior L-Asparaginase and PD-1 Blockade},
  journal = {The Oncologist},
  year = {2024},
  doi = {10.1093/oncolo/oyad241}
}
Kostenlos starten →